Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2022

May 17, 2022

SELL
$2.42 - $3.98 $94,380 - $155,220
-39,000 Reduced 14.73%
225,700 $673,000
Q4 2021

Feb 15, 2022

BUY
$3.11 - $4.61 $243,824 - $361,424
78,400 Added 42.08%
264,700 $1.03 Million
Q3 2021

Nov 16, 2021

BUY
$2.65 - $4.62 $381,335 - $664,818
143,900 Added 339.39%
186,300 $799,000
Q2 2021

Aug 16, 2021

SELL
$2.5 - $3.51 $11,250 - $15,794
-4,500 Reduced 9.59%
42,400 $128,000
Q1 2021

May 18, 2021

SELL
$3.14 - $4.84 $109,272 - $168,432
-34,800 Reduced 42.59%
46,900 $156,000
Q4 2020

Feb 17, 2021

BUY
$2.76 - $4.97 $225,491 - $406,049
81,700 New
81,700 $290,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $478M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.